Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean glycol and kaolin and methyl and zinc oxide?
Displaying drugs 751 - 775 of 15589 in total

Rezafungin

Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Iupac: … {4-[4'-(pentyloxy)-[1,1'-biphenyl]-4-yl]phenyl})methylidene]amino]-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl …
Matched Description: … _Candida tropicalis_, as well as other _Candida_ and _Aspergillus_ spp. ... Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Solriamfetol

Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label].
Approved
Matched Description: … Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Dopamine And Norepinephrine Reuptake Inhibitors ... Psychostimulants, Agents Used for ADHD and Nootropics …

Palivizumab

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains...
Approved
Investigational
Matched Description: … regions of the VH genes Cor (1) and Cess (2). ... Synagis is a composite of human (95%) and murine (5%) antibody sequences. ... 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF) …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Conestat alfa

C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within...
Approved
Investigational
Matched Description: … tPA and plasmin within the fibrinolytic pathway. ... Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system. ... The primary function of endogenous C1INH is to regulate the activation of the complement and contact …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Antithrombin III human

A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Approved
Matched Description: … A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Celiprolol

Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina ... It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 …

Chymopapain

Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. It is an extracellular plant cysteine proteinase similar to papain in specificity. Chymopapain was developed by Chart Medcl and FDA approved...
Approved
Withdrawn
Matched Description: … [A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. …
Matched Categories: … Enzymes and Coenzymes …

Certoparin

Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.
Approved
Investigational
Matched Categories: … Heparin and similars …

Viltolarsen

Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … [A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. ... dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Fexinidazole

Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focussed control efforts. Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first...
Approved
Investigational
Matched Iupac: … 1-methyl-2-{[4-(methylsulfanyl)phenoxy]methyl}-5-nitro-1H-imidazole …
Matched Description: … trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by _T. brucei gambiense_ and ... [nifurtimox]/[eflornithine] combination therapy (NECT), though [melarsoprol] is highly toxic and each ... meningoencephalitic) stage in which patients experience progressively worsening neurological symptoms and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Miglustat

Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Miglustat is now...
Approved
Matched Description: … patients in the European Union, Brazil, and South Korea. ... Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C ... It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of ... 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …

Atezolizumab

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Durvalumab

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Avelumab

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … ] and Health Canada,[L48171] respectively. ... programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Pentoxifylline

Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties.[A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for its possible...
Approved
Investigational
Matched Description: … also has both anti-oxidant and anti-inflammatory properties. ... Pharmaceuticals and APOTEX have been available since the late 1990s. ... (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and …

Ethchlorvynol

Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
Approved
Illicit
Withdrawn
Matched Description: … Ethchlorvynol is a sedative and hypnotic drug. ... It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance …
Matched Categories: … Hypnotics and Sedatives …

Bisoxatin

Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions ... It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and …
Matched Categories: … Alimentary Tract and Metabolism …

Valdecoxib

Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Iupac: … 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide …
Matched Description: … ., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke …
Matched Categories: … Genito Urinary System and Sex Hormones ... Antiinflammatory and Antirheumatic Products ... Gynecological Antiinfectives and Antiseptics ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Piperaquine

Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative DB11638 as part of...
Approved
Experimental
Investigational
Matched Description: … Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550 ... Its use declined in the 1980's as piperaquine resistant strains of *Plasmodium falciparum* appeared and …
Matched Categories: … artenimol and piperaquine ... arterolane and piperaquine ... artemisinin and piperaquine ... Antiparasitic Products, Insecticides and Repellents …

Drotaverine

Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia, parainfluenza, and ... symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and …
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives …

Givosiran

Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States ... genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and ... non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Bevacizumab

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Description: … [A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and ... of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and ... [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Technetium Tc-99m nofetumomab merpentan

Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma...
Approved
Withdrawn
Matched Description: … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14 ... NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Vespula maculifrons venom protein

Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Displaying drugs 751 - 775 of 15589 in total